[Retracted] 14‑3‑3β exerts glioma‑promoting effects and is associated with malignant progression and poor prognosis in patients with glioma.

[This retracts the article DOI: 10.3892/etm.2017.

[Retracted] Knockdown of PREX2a inhibits the malignant phenotype of glioma cells.

Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that cell invasion assay data in the article (featured in Fig. 4A) were strikingly similar to data appearing in different form in another article by different authors at different research institutions, which had already been published elsewhere at the time of the present article's submission. Furthermore, flow cytometric data featured in Fig.

14-3-3β exerts glioma-promoting effects and is associated with malignant progression and poor prognosis in patients with glioma.

Glioma is a type of tumor that affects the central nervous system. It has been demonstrated that 14-3-3β, a protein that is mainly concentrated in the brain, serves an important role in tumor regulation. However, the mechanism of action of 14-3-3β that underlies the pathogenesis of glioma remains to be elucidated.

Knockdown of PREX2a inhibits the malignant phenotype of glioma cells.

Glioma is the most common type of malignant brain tumor. Phosphatidylinositol‑3,4,5‑trisphosphate‑dependent Rac exchange factor 2a (PREX2a), which is a regulator of the small guanosine triphosphatase Rac, has previously been identified as an oncoprotein that inhibits phosphatase and tensin homolog deleted on chromosome 10 (PTEN) activity. However, the role of PREX2a in the regulation of the malignant phenotype of glioma has yet to be reported.